Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy

Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures....

Full description

Saved in:
Bibliographic Details
Published inBone (New York, N.Y.) Vol. 52; no. 1; pp. 360 - 365
Main Authors Chiang, Cherie Ying, Zebaze, Roger M.D., Ghasem-Zadeh, Ali, Iuliano-Burns, Sandra, Hardidge, Andrew, Seeman, Ego
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier Inc 01.01.2013
Elsevier
Subjects
Online AccessGet full text
ISSN8756-3282
1873-2763
1873-2763
DOI10.1016/j.bone.2012.10.006

Cover

Abstract Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures. The aim of this study was to determine whether teriparatide therapy assists in fracture healing and improves bone quality in patients with bisphosphonate associated atypical femoral fractures. A prospective study was conducted involving 14 consecutive patients presenting during 2years with atypical femoral fracture. All patients were offered teriparatide therapy unless contraindicated. Age and sex matched control subjects without fragility fractures or anti-resorptive treatment were recruited. High resolution peripheral micro-computed tomography (HRpQCT) scans of the distal radius and distal tibia were analysed for their cortical bone tissue mineralisation density using new software (StrAx1.0, StrAxCorp, Australia) at baseline and 6months after teriparatide. Administration of 20μg of teriparatide subcutaneously daily for 6months to 5 of the 14 patients was associated with 2–3 fold increase in bone remodelling markers (p=0.01) and fracture healing. At the distal radius, the proportion of less densely mineralised bone increased by 29.5% (p=0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% (p=0.03). Similar observations were made at the distal tibia. Of the nine patients managed conservatively or surgically, seven had poor fracture healing with ongoing pain, one sustained a contralateral atypical fracture and one had fracture union after 1year. Teriparatide may assist in healing of atypical fractures and restoration of bone quality. ► Bisphosphonates suppress bone remodelling, which can lead to microdamage accumulation and atypical femoral fractures. ► Teriparatide given to five patients with atypical fractures was associated with an increase in bone remodelling markers and fracture healing. ► The volume of less densely and more heterogeneously mineralised bone increased and the proportion of older, more densely mineralised bone decreased. ► Teriparatide may assist in healing of atypical fractures and restoration of bone quality.
AbstractList Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures. The aim of this study was to determine whether teriparatide therapy assists in fracture healing and improves bone quality in patients with bisphosphonate associated atypical femoral fractures. A prospective study was conducted involving 14 consecutive patients presenting during 2 years with atypical femoral fracture. All patients were offered teriparatide therapy unless contraindicated. Age and sex matched control subjects without fragility fractures or anti-resorptive treatment were recruited. High resolution peripheral micro-computed tomography (HRpQCT) scans of the distal radius and distal tibia were analysed for their cortical bone tissue mineralisation density using new software (StrAx1.0, StrAxCorp, Australia) at baseline and 6 months after teriparatide. Administration of 20 μg of teriparatide subcutaneously daily for 6 months to 5 of the 14 patients was associated with 2-3 fold increase in bone remodelling markers (p=0.01) and fracture healing. At the distal radius, the proportion of less densely mineralised bone increased by 29.5% (p=0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% (p=0.03). Similar observations were made at the distal tibia. Of the nine patients managed conservatively or surgically, seven had poor fracture healing with ongoing pain, one sustained a contralateral atypical fracture and one had fracture union after 1 year. Teriparatide may assist in healing of atypical fractures and restoration of bone quality.Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures. The aim of this study was to determine whether teriparatide therapy assists in fracture healing and improves bone quality in patients with bisphosphonate associated atypical femoral fractures. A prospective study was conducted involving 14 consecutive patients presenting during 2 years with atypical femoral fracture. All patients were offered teriparatide therapy unless contraindicated. Age and sex matched control subjects without fragility fractures or anti-resorptive treatment were recruited. High resolution peripheral micro-computed tomography (HRpQCT) scans of the distal radius and distal tibia were analysed for their cortical bone tissue mineralisation density using new software (StrAx1.0, StrAxCorp, Australia) at baseline and 6 months after teriparatide. Administration of 20 μg of teriparatide subcutaneously daily for 6 months to 5 of the 14 patients was associated with 2-3 fold increase in bone remodelling markers (p=0.01) and fracture healing. At the distal radius, the proportion of less densely mineralised bone increased by 29.5% (p=0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% (p=0.03). Similar observations were made at the distal tibia. Of the nine patients managed conservatively or surgically, seven had poor fracture healing with ongoing pain, one sustained a contralateral atypical fracture and one had fracture union after 1 year. Teriparatide may assist in healing of atypical fractures and restoration of bone quality.
Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures. The aim of this study was to determine whether teriparatide therapy assists in fracture healing and improves bone quality in patients with bisphosphonate associated atypical femoral fractures. A prospective study was conducted involving 14 consecutive patients presenting during 2years with atypical femoral fracture. All patients were offered teriparatide therapy unless contraindicated. Age and sex matched control subjects without fragility fractures or anti-resorptive treatment were recruited. High resolution peripheral micro-computed tomography (HRpQCT) scans of the distal radius and distal tibia were analysed for their cortical bone tissue mineralisation density using new software (StrAx1.0, StrAxCorp, Australia) at baseline and 6months after teriparatide. Administration of 20 mu g of teriparatide subcutaneously daily for 6months to 5 of the 14 patients was associated with 2-3 fold increase in bone remodelling markers (p=0.01) and fracture healing. At the distal radius, the proportion of less densely mineralised bone increased by 29.5% (p=0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% (p=0.03). Similar observations were made at the distal tibia. Of the nine patients managed conservatively or surgically, seven had poor fracture healing with ongoing pain, one sustained a contralateral atypical fracture and one had fracture union after 1year. Teriparatide may assist in healing of atypical fractures and restoration of bone quality.
Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures. The aim of this study was to determine whether teriparatide therapy assists in fracture healing and improves bone quality in patients with bisphosphonate associated atypical femoral fractures. A prospective study was conducted involving 14 consecutive patients presenting during 2years with atypical femoral fracture. All patients were offered teriparatide therapy unless contraindicated. Age and sex matched control subjects without fragility fractures or anti-resorptive treatment were recruited. High resolution peripheral micro-computed tomography (HRpQCT) scans of the distal radius and distal tibia were analysed for their cortical bone tissue mineralisation density using new software (StrAx1.0, StrAxCorp, Australia) at baseline and 6months after teriparatide. Administration of 20μg of teriparatide subcutaneously daily for 6months to 5 of the 14 patients was associated with 2–3 fold increase in bone remodelling markers (p=0.01) and fracture healing. At the distal radius, the proportion of less densely mineralised bone increased by 29.5% (p=0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% (p=0.03). Similar observations were made at the distal tibia. Of the nine patients managed conservatively or surgically, seven had poor fracture healing with ongoing pain, one sustained a contralateral atypical fracture and one had fracture union after 1year. Teriparatide may assist in healing of atypical fractures and restoration of bone quality. ► Bisphosphonates suppress bone remodelling, which can lead to microdamage accumulation and atypical femoral fractures. ► Teriparatide given to five patients with atypical fractures was associated with an increase in bone remodelling markers and fracture healing. ► The volume of less densely and more heterogeneously mineralised bone increased and the proportion of older, more densely mineralised bone decreased. ► Teriparatide may assist in healing of atypical fractures and restoration of bone quality.
Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures. The aim of this study was to determine whether teriparatide therapy assists in fracture healing and improves bone quality in patients with bisphosphonate associated atypical femoral fractures. A prospective study was conducted involving 14 consecutive patients presenting during 2 years with atypical femoral fracture. All patients were offered teriparatide therapy unless contraindicated. Age and sex matched control subjects without fragility fractures or anti-resorptive treatment were recruited. High resolution peripheral micro-computed tomography (HRpQCT) scans of the distal radius and distal tibia were analysed for their cortical bone tissue mineralisation density using new software (StrAx1.0, StrAxCorp, Australia) at baseline and 6 months after teriparatide. Administration of 20 μg of teriparatide subcutaneously daily for 6 months to 5 of the 14 patients was associated with 2-3 fold increase in bone remodelling markers (p=0.01) and fracture healing. At the distal radius, the proportion of less densely mineralised bone increased by 29.5% (p=0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% (p=0.03). Similar observations were made at the distal tibia. Of the nine patients managed conservatively or surgically, seven had poor fracture healing with ongoing pain, one sustained a contralateral atypical fracture and one had fracture union after 1 year. Teriparatide may assist in healing of atypical fractures and restoration of bone quality.
Abstract Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when remodelling suppression is protracted, bone quality may be compromised predisposing to microdamage accumulation and atypical femoral fractures. The aim of this study was to determine whether teriparatide therapy assists in fracture healing and improves bone quality in patients with bisphosphonate associated atypical femoral fractures. A prospective study was conducted involving 14 consecutive patients presenting during 2 years with atypical femoral fracture. All patients were offered teriparatide therapy unless contraindicated. Age and sex matched control subjects without fragility fractures or anti-resorptive treatment were recruited. High resolution peripheral micro-computed tomography (HRpQCT) scans of the distal radius and distal tibia were analysed for their cortical bone tissue mineralisation density using new software (StrAx1.0, StrAxCorp, Australia) at baseline and 6 months after teriparatide. Administration of 20 μg of teriparatide subcutaneously daily for 6 months to 5 of the 14 patients was associated with 2–3 fold increase in bone remodelling markers ( p = 0.01) and fracture healing. At the distal radius, the proportion of less densely mineralised bone increased by 29.5% ( p = 0.01), and the proportion of older, more densely mineralised bone decreased by 16.2% ( p = 0.03). Similar observations were made at the distal tibia. Of the nine patients managed conservatively or surgically, seven had poor fracture healing with ongoing pain, one sustained a contralateral atypical fracture and one had fracture union after 1 year. Teriparatide may assist in healing of atypical fractures and restoration of bone quality.
Author Hardidge, Andrew
Chiang, Cherie Ying
Iuliano-Burns, Sandra
Ghasem-Zadeh, Ali
Seeman, Ego
Zebaze, Roger M.D.
Author_xml – sequence: 1
  givenname: Cherie Ying
  surname: Chiang
  fullname: Chiang, Cherie Ying
  email: cherie@cheriechiang.com
  organization: Department of Endocrinology, Austin Health, University of Melbourne, Melbourne, Australia
– sequence: 2
  givenname: Roger M.D.
  surname: Zebaze
  fullname: Zebaze, Roger M.D.
  email: zebaze@unimelb.edu.au
  organization: Department of Endocrinology, Austin Health, University of Melbourne, Melbourne, Australia
– sequence: 3
  givenname: Ali
  surname: Ghasem-Zadeh
  fullname: Ghasem-Zadeh, Ali
  email: alig@unimelb.edu.au
  organization: Department of Endocrinology, Austin Health, University of Melbourne, Melbourne, Australia
– sequence: 4
  givenname: Sandra
  surname: Iuliano-Burns
  fullname: Iuliano-Burns, Sandra
  email: sandraib@unimelb.edu.au
  organization: Department of Endocrinology, Austin Health, University of Melbourne, Melbourne, Australia
– sequence: 5
  givenname: Andrew
  surname: Hardidge
  fullname: Hardidge, Andrew
  email: Andrew.HARDIDGE@austin.org.au
  organization: Department of Orthopaedic Surgery, Austin Health, University of Melbourne, Melbourne, Australia
– sequence: 6
  givenname: Ego
  surname: Seeman
  fullname: Seeman, Ego
  email: egos@unimelb.edu.au
  organization: Department of Endocrinology, Austin Health, University of Melbourne, Melbourne, Australia
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27153041$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/23072919$$D View this record in MEDLINE/PubMed
BookMark eNqNkl1rFDEUhoNU7Lb6B7yQ3AjezJqPmUlGRJBSP6DghfU6ZJKzbtbZyTTJVObfN2FXhYLVi3DC4XlPyPueM3Qy-hEQek7JmhLavt6t-9xYM0JZbqwJaR-hFZWCV0y0_AStpGjaijPJTtFZjDtCCO8EfYJOGSeCdbRboXgNwU066OQsYLefgr-FiMtgfDPrwaUF69HiLeT7-B37DdZpmZzRA97A3odSgzZpDlmmY_TG6QQW_3Rpi3sXp60vZ8xNnLYQ9LQ8RY83eojw7FjP0bcPl9cXn6qrLx8_X7y_qkzTdqmydWe5kEJSQ4zQjda95Qxq2cleMtmynrRcMACoLSdcSpBU09p2RGveNz0_R68Oc_OnbmaISe1dNDAMegQ_R0VZI0RDWdv8B8qorGXbkIy-OKJzvwerpuD2Oizql6cZeHkEdMw2ZXdG4-IfTtCGk5pmjh04E3yMATa_EUpUCVjtVMlBlYBLLwecRfKeyLiUw_NjCtoND0vfHqSQPb91EFQ0DkYD1gUwSVnvHpa_uyc3eSPKIvyABeLOz2HMaSqqIlNEfS3LV3aP5iGc8mLcm78P-Nfrd5Sk6fs
CitedBy_id crossref_primary_10_1007_s12018_017_9239_3
crossref_primary_10_1016_j_tcr_2017_10_014
crossref_primary_10_1016_j_beem_2014_09_003
crossref_primary_10_1016_j_jogc_2022_03_004
crossref_primary_10_4184_asj_2014_8_4_498
crossref_primary_10_1016_j_bonr_2020_100249
crossref_primary_10_4158_GL_2020_0524SUPPL
crossref_primary_10_1097_BCO_0000000000000278
crossref_primary_10_1210_clinem_dgz295
crossref_primary_10_1186_s13256_015_0590_z
crossref_primary_10_1148_rg_2015140301
crossref_primary_10_1016_j_jos_2017_10_008
crossref_primary_10_1007_s00198_021_05948_w
crossref_primary_10_1016_j_bone_2020_115726
crossref_primary_10_1016_j_bonr_2017_01_002
crossref_primary_10_3928_01477447_20151020_16
crossref_primary_10_1007_s00198_023_06768_w
crossref_primary_10_5794_jjoms_62_244
crossref_primary_10_1097_BOT_0000000000000851
crossref_primary_10_1016_j_semarthrit_2014_09_005
crossref_primary_10_1038_bonekey_2014_54
crossref_primary_10_1007_s11914_021_00696_6
crossref_primary_10_1016_j_jbo_2019_100259
crossref_primary_10_1177_2309499017727916
crossref_primary_10_4055_jkoa_2024_59_1_9
crossref_primary_10_1016_j_jcte_2016_05_004
crossref_primary_10_1259_bjr_20150725
crossref_primary_10_1517_14712598_2015_977249
crossref_primary_10_1097_BOR_0000000000000057
crossref_primary_10_15369_sujms_31_73
crossref_primary_10_1007_s13346_017_0394_3
crossref_primary_10_11005_jbm_2017_24_1_65
crossref_primary_10_5812_traumamon_42869
crossref_primary_10_2106_JBJS_RVW_N_00062
crossref_primary_10_1007_s00774_014_0617_3
crossref_primary_10_1007_s00198_018_4507_8
crossref_primary_10_1097_BOT_0000000000000743
crossref_primary_10_1055_s_0041_1740995
crossref_primary_10_1002_jbm4_10250
crossref_primary_10_1097_BOT_0000000000000508
crossref_primary_10_3390_children9020268
crossref_primary_10_1007_s00774_014_0606_6
crossref_primary_10_1016_j_bone_2019_08_006
crossref_primary_10_1177_21514593221090392
crossref_primary_10_1007_s00198_017_4155_4
crossref_primary_10_47671_10_47671_TVG_78_22_063
crossref_primary_10_1016_j_jogc_2021_09_013
crossref_primary_10_1007_s00402_023_05171_8
crossref_primary_10_1016_j_bone_2013_11_016
crossref_primary_10_1111_joa_12533
crossref_primary_10_1007_s13670_016_0161_1
crossref_primary_10_1080_24725625_2017_1361373
crossref_primary_10_1002_jbmr_1998
crossref_primary_10_1021_acs_biomac_7b00750
crossref_primary_10_1186_s13063_021_05556_3
crossref_primary_10_1080_14397595_2017_1362093
crossref_primary_10_1007_s00198_018_4658_7
crossref_primary_10_11005_jbm_2023_30_3_209
crossref_primary_10_1007_s00198_016_3513_y
crossref_primary_10_11005_jbm_2020_27_3_167
crossref_primary_10_1530_EJE_17_1002
crossref_primary_10_17816_vto201320377_81
crossref_primary_10_4158_EP14315_OR
crossref_primary_10_1007_s00198_015_3354_0
crossref_primary_10_1177_2210491720952444
crossref_primary_10_1016_j_jor_2017_01_002
crossref_primary_10_1016_j_jbo_2023_100478
crossref_primary_10_1007_s00223_024_01244_x
crossref_primary_10_3390_bioengineering7010022
crossref_primary_10_4103_jbjd_jbjd_34_22
crossref_primary_10_1016_j_bonr_2014_10_004
crossref_primary_10_12671_jkfs_2018_31_4_159
crossref_primary_10_1186_1756_0500_6_11
crossref_primary_10_1016_j_bone_2015_06_017
crossref_primary_10_1007_s11914_019_00501_5
crossref_primary_10_1016_j_otsr_2022_103475
crossref_primary_10_3389_fsurg_2022_1063170
crossref_primary_10_1016_j_jecr_2017_12_002
crossref_primary_10_1007_s00198_015_3331_7
crossref_primary_10_1016_j_bone_2018_01_033
crossref_primary_10_13004_kjnt_2016_12_2_123
crossref_primary_10_3390_medicina60111814
crossref_primary_10_14260_jemds_2014_3586
crossref_primary_10_1002_jbm4_10387
crossref_primary_10_1007_s00590_016_1742_6
crossref_primary_10_1007_s13670_013_0045_6
crossref_primary_10_1155_2013_249872
crossref_primary_10_22159_ajpcr_2021_v14i11_43135
crossref_primary_10_1007_s00774_025_01589_9
crossref_primary_10_47671_TVG_78_22_063
crossref_primary_10_1016_j_bone_2020_115671
crossref_primary_10_1097_BOT_0000000000001116
crossref_primary_10_1002_jor_24953
crossref_primary_10_1016_j_bone_2013_01_007
crossref_primary_10_11005_jbm_2015_22_4_183
crossref_primary_10_4103_ortho_IJOrtho_315_17
crossref_primary_10_1007_s40520_013_0133_7
crossref_primary_10_1002_jbmr_2424
crossref_primary_10_1111_os_12307
crossref_primary_10_2106_JBJS_CC_15_00172
crossref_primary_10_1007_s00198_017_4286_7
crossref_primary_10_1097_01_med_0000436194_10599_94
crossref_primary_10_1302_0301_620X_99B3_BJJ_2016_1144_R1
crossref_primary_10_1186_s12891_017_1878_5
crossref_primary_10_1007_s13554_014_0013_5
crossref_primary_10_1007_s43465_022_00639_y
crossref_primary_10_1007_s00256_016_2346_2
crossref_primary_10_1007_s00774_022_01378_8
crossref_primary_10_1007_s12603_015_0652_3
crossref_primary_10_1007_s11914_014_0239_7
Cites_doi 10.1002/jor.21448
10.1359/jbmr.2000.15.4.613
10.3233/THC-1998-65-606
10.1007/s00198-008-0754-4
10.1002/jbmr.253
10.1359/jbmr.070609
10.1007/s00223-011-9500-6
10.1097/BOT.0b013e3181b6499b
10.1016/j.bone.2010.05.019
10.1056/NEJMoa1010650
10.1007/s00223-010-9360-5
10.2106/JBJS.J.01379
10.1359/JBMR.051109
10.1038/206489a0
10.1016/j.bone.2006.04.028
10.1007/s11999-011-1985-9
10.1016/j.bone.2007.11.011
10.1001/jama.2011.190
10.1210/jc.2011-0593
10.1002/jbmr.233
10.1359/jbmr.060314
10.1210/jc.2010-2520
10.1001/archinte.164.18.2024
10.1359/jbmr.090731
10.1056/NEJMra053077
10.1056/NEJMc1002684
10.1016/j.bone.2011.09.042
10.1002/jbmr.261
10.1016/j.bone.2004.07.016
10.1210/jc.2002-021988
10.1007/s11914-005-0004-z
10.1016/0021-9290(69)90036-0
ContentType Journal Article
Copyright 2012
2014 INIST-CNRS
Crown Copyright © 2012. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2012
– notice: 2014 INIST-CNRS
– notice: Crown Copyright © 2012. Published by Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7QP
DOI 10.1016/j.bone.2012.10.006
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Calcium & Calcified Tissue Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
Calcium & Calcified Tissue Abstracts
DatabaseTitleList MEDLINE - Academic
Calcium & Calcified Tissue Abstracts

MEDLINE


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 1873-2763
EndPage 365
ExternalDocumentID 23072919
27153041
10_1016_j_bone_2012_10_006
S8756328212013130
1_s2_0_S8756328212013130
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
1B1
1P~
1~.
1~5
23N
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABGSF
ABJNI
ABLJU
ABMAC
ABMZM
ABUDA
ABWVN
ABXDB
ACDAQ
ACGFS
ACIEU
ACIUM
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADUVX
AEBSH
AEHWI
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGRDE
AGUBO
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEB
HMK
HMO
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OF0
OR.
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SPCBC
SSH
SSU
SSZ
T5K
WUQ
X7M
Z5R
ZGI
ZMT
~02
~G-
1RT
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
RIG
AAIAV
ABLVK
ABYKQ
AHPSJ
AJBFU
DOVZS
EFLBG
LCYCR
ZA5
AAYXX
AGRNS
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ACLOT
~HD
7QP
ID FETCH-LOGICAL-c569t-d49d378781c0c7a5aabd32e4898b82862b06372eee4d30388e81a14d90aa3b5b3
IEDL.DBID AIKHN
ISSN 8756-3282
1873-2763
IngestDate Sat Sep 27 17:08:48 EDT 2025
Sat Sep 27 18:04:45 EDT 2025
Thu Apr 03 06:57:08 EDT 2025
Wed Apr 02 07:26:45 EDT 2025
Tue Jul 01 03:41:26 EDT 2025
Thu Apr 24 22:55:57 EDT 2025
Fri Feb 23 02:22:08 EST 2024
Sun Feb 23 10:18:48 EST 2025
Tue Aug 26 16:32:49 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords High resolution computed tomography
Osteoporosis
Bisphosphonates
Atypical femur fractures
Teriparatide
Femur
High resolution
Antiosteoporotic
Radiodiagnosis
Diseases of the osteoarticular system
Fracture
Trauma
Treatment
Antiosteoclastic agent
Morphology
Quality
Medical imagery
Atypical
Computerized axial tomography
Bone
Cicatrization
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
CC BY 4.0
Crown Copyright © 2012. Published by Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c569t-d49d378781c0c7a5aabd32e4898b82862b06372eee4d30388e81a14d90aa3b5b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
OpenAccessLink http://hdl.handle.net/11343/41859
PMID 23072919
PQID 1221848650
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_1257751265
proquest_miscellaneous_1221848650
pubmed_primary_23072919
pascalfrancis_primary_27153041
crossref_primary_10_1016_j_bone_2012_10_006
crossref_citationtrail_10_1016_j_bone_2012_10_006
elsevier_sciencedirect_doi_10_1016_j_bone_2012_10_006
elsevier_clinicalkeyesjournals_1_s2_0_S8756328212013130
elsevier_clinicalkey_doi_10_1016_j_bone_2012_10_006
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-01-01
PublicationDateYYYYMMDD 2013-01-01
PublicationDate_xml – month: 01
  year: 2013
  text: 2013-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Amsterdam
PublicationPlace_xml – name: Amsterdam
– name: United States
PublicationTitle Bone (New York, N.Y.)
PublicationTitleAlternate Bone
PublicationYear 2013
Publisher Elsevier Inc
Elsevier
Publisher_xml – name: Elsevier Inc
– name: Elsevier
References Seeman (bb0015) 2010; 25
Currey (bb0020) 2005; 3
Cheung, Seeman (bb0075) 2010; 363
Yeni, Zelman, Divine, Kim, Fyhrie (bb0105) 2008; 42
Lindsay, Scheele, Neer, Pohl, Adami, Mautalen, Reginster, Stepan, Myers, Mitlak (bb0050) 2004; 164
Jobke, Muche, Burghardt, Semler, Link, Majumdar (bb0150) 2011; 89
Currey (bb0115) 1969; 2
Hattner, Epker, Frost (bb0005) 1965; 206
Mashiba, Hirano, Turner, Forwood, Johnston, Burr (bb0130) 2000; 15
Tang, Allen, Phipps, Burr, Vashishth (bb0110) 2009; 20
Lindsay, Cosman, Zhou, Bostrom, Shen, Cruz, Nieves, Dempster (bb0160) 2006; 21
Schilcher, Michaelsson, Aspenberg (bb0090) 2011; 364
Giusti, Hamdy, Papapoulos (bb0100) 2010; 47
Karim, Vashishth (bb0025) 2011; 29
Chapurlat, Arlot, Burt-Pichat, Chavassieux, Roux, Portero-Muzy, Delmas (bb0140) 2007; 22
Shane, Burr, Ebeling, Abrahamsen, Adler, Brown, Cheung, Cosman, Curtis, Dell, Dempster, Einhorn, Genant, Geusens, Klaushofer, Koval, Lane, McKiernan, McKinney, Ng, Nieves, O'Keefe, Papapoulos, Sen, Van der Meulen, Weinstein, Whyte (bb0035) 2010; 25
Park-Wyllie, Mamdani, Juurlink, Hawker, Gunraj, Austin, Whelan, Weiler, Laupacis (bb0045) 2011; 305
Misof, Roschger, Cosman, Kurland, Tesch, Messmer, Dempster, Nieves, Shane, Fratzl, Klaushofer, Bilezikian, Lindsay (bb0170) 2003; 88
Wang, Bhattacharyya (bb0095) 2011; 26
Allen, Iwata, Phipps, Burr (bb0135) 2006; 39
Laib, Hauselmann, Ruegsegger (bb0080) 1998; 6
Ellegaard, Jorgensen, Schwarz (bb0145) 2010; 87
Peichl, Holzer, Maier, Holzer (bb0055) 2011; 93
Gomberg, Wustrack, Napoli, Arnaud, Black (bb0065) 2011; 96
Zebaze, GhasemZadeh, Seeman (bb0085) 2011
Currey (bb0030) 2005; 5
Carvalho, Voss, Almeida, Salgado, Bandeira (bb0070) 2011; 96
Aspenberg, Genant, Johansson, Nino, See, Krohn, García-Hernández, Recknor, Einhorn, Dalsky, Mitlak, Fierlinger, Lakshmanan (bb0060) 2010; 25
Seeman, Delmas (bb0010) 2006; 354
Ma, Zeng, Donley, Ste-Marie, Gallagher, Dalsky, Marcus, Eriksen (bb0155) 2006; 21
Koh, Goh, Png, Kwek, Howe (bb0040) 2010; 24
Nalla, Kruzic, Kinney, Ritchie (bb0120) 2004; 35
Unnanuntana, Ashfaq, Ton, Kleimeyer, Lane (bb0165) 2012; 470
Tjhia, Odvina, Rao, Stover, Wang, Fyhrie (bb0125) 2011; 49
Cheung (10.1016/j.bone.2012.10.006_bb0075) 2010; 363
Mashiba (10.1016/j.bone.2012.10.006_bb0130) 2000; 15
Tang (10.1016/j.bone.2012.10.006_bb0110) 2009; 20
Jobke (10.1016/j.bone.2012.10.006_bb0150) 2011; 89
Wang (10.1016/j.bone.2012.10.006_bb0095) 2011; 26
Unnanuntana (10.1016/j.bone.2012.10.006_bb0165) 2012; 470
Zebaze (10.1016/j.bone.2012.10.006_bb0085) 2011
Chapurlat (10.1016/j.bone.2012.10.006_bb0140) 2007; 22
Ma (10.1016/j.bone.2012.10.006_bb0155) 2006; 21
Gomberg (10.1016/j.bone.2012.10.006_bb0065) 2011; 96
Nalla (10.1016/j.bone.2012.10.006_bb0120) 2004; 35
Lindsay (10.1016/j.bone.2012.10.006_bb0160) 2006; 21
Aspenberg (10.1016/j.bone.2012.10.006_bb0060) 2010; 25
Karim (10.1016/j.bone.2012.10.006_bb0025) 2011; 29
Carvalho (10.1016/j.bone.2012.10.006_bb0070) 2011; 96
Allen (10.1016/j.bone.2012.10.006_bb0135) 2006; 39
Park-Wyllie (10.1016/j.bone.2012.10.006_bb0045) 2011; 305
Misof (10.1016/j.bone.2012.10.006_bb0170) 2003; 88
Ellegaard (10.1016/j.bone.2012.10.006_bb0145) 2010; 87
Shane (10.1016/j.bone.2012.10.006_bb0035) 2010; 25
Currey (10.1016/j.bone.2012.10.006_bb0115) 1969; 2
Giusti (10.1016/j.bone.2012.10.006_bb0100) 2010; 47
Hattner (10.1016/j.bone.2012.10.006_bb0005) 1965; 206
Tjhia (10.1016/j.bone.2012.10.006_bb0125) 2011; 49
Seeman (10.1016/j.bone.2012.10.006_bb0015) 2010; 25
Currey (10.1016/j.bone.2012.10.006_bb0020) 2005; 3
Peichl (10.1016/j.bone.2012.10.006_bb0055) 2011; 93
Yeni (10.1016/j.bone.2012.10.006_bb0105) 2008; 42
Lindsay (10.1016/j.bone.2012.10.006_bb0050) 2004; 164
Koh (10.1016/j.bone.2012.10.006_bb0040) 2010; 24
Currey (10.1016/j.bone.2012.10.006_bb0030) 2005; 5
Schilcher (10.1016/j.bone.2012.10.006_bb0090) 2011; 364
Laib (10.1016/j.bone.2012.10.006_bb0080) 1998; 6
Seeman (10.1016/j.bone.2012.10.006_bb0010) 2006; 354
References_xml – volume: 88
  start-page: 1150
  year: 2003
  end-page: 1156
  ident: bb0170
  article-title: Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment
  publication-title: J Clin Endocrinol Metab
– volume: 25
  start-page: 2267
  year: 2010
  end-page: 2294
  ident: bb0035
  article-title: Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research
  publication-title: J Bone Miner Res
– volume: 2
  start-page: 1
  year: 1969
  end-page: 11
  ident: bb0115
  article-title: The mechanical consequences of variation in the mineral content of bone
  publication-title: J Biomech
– volume: 35
  start-page: 1240
  year: 2004
  end-page: 1246
  ident: bb0120
  article-title: Effect of aging on the toughness of human cortical bone: evaluation by R-curves
  publication-title: Bone
– volume: 29
  start-page: 1
  year: 2011
  end-page: 6
  ident: bb0025
  article-title: Role of trabecular microarchitecture in the formation, accumulation, and morphology of microdamage in human cancellous bone
  publication-title: J Orthop Res
– volume: 47
  start-page: 169
  year: 2010
  end-page: 180
  ident: bb0100
  article-title: Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies
  publication-title: Bone
– volume: 22
  start-page: 1502
  year: 2007
  end-page: 1509
  ident: bb0140
  article-title: Microcrack frequency and bone remodelling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study
  publication-title: J Bone Miner Res
– volume: 164
  start-page: 2024
  year: 2004
  end-page: 2030
  ident: bb0050
  article-title: Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
  publication-title: Arch Intern Med
– volume: 21
  start-page: 855
  year: 2006
  end-page: 864
  ident: bb0155
  article-title: Teriparatide increases bone formation in modeling and remodelling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis
  publication-title: J Bone Miner Res
– volume: 25
  start-page: 404
  year: 2010
  end-page: 414
  ident: bb0060
  article-title: Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures
  publication-title: J Bone Miner Res
– volume: 87
  start-page: 1
  year: 2010
  end-page: 13
  ident: bb0145
  article-title: Parathyroid hormone and bone healing
  publication-title: Calcif Tissue Int
– volume: 470
  start-page: 291
  year: 2012
  end-page: 298
  ident: bb0165
  article-title: The effect of long-term alendronate treatment on cortical thickness of the proximal femur
  publication-title: Clin Orthop Relat Res
– volume: 6
  start-page: 329
  year: 1998
  end-page: 337
  ident: bb0080
  article-title: In vivo high resolution 3D-QCT of the human forearm
  publication-title: Technol Health Care
– volume: 15
  start-page: 613
  year: 2000
  end-page: 620
  ident: bb0130
  article-title: Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib
  publication-title: J Bone Miner Res
– volume: 93
  start-page: 1583
  year: 2011
  end-page: 1587
  ident: bb0055
  article-title: Parathyroid hormone 1–84 accelerates fracture-healing in pubic bones of elderly osteoporotic women
  publication-title: J Bone Joint Surg
– volume: 42
  start-page: 591
  year: 2008
  end-page: 596
  ident: bb0105
  article-title: Trabecular shear stress amplification and variability in human vertebral cancellous bone: relationship with age, gender, spine level and trabecular architecture
  publication-title: Bone
– volume: 26
  start-page: 553
  year: 2011
  end-page: 560
  ident: bb0095
  article-title: Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007
  publication-title: J Bone Miner Res
– volume: 354
  start-page: 2250
  year: 2006
  end-page: 2261
  ident: bb0010
  article-title: Bone quality–the material and structural basis of bone strength and fragility
  publication-title: N Engl J Med
– volume: 25
  start-page: 2553
  year: 2010
  end-page: 2557
  ident: bb0015
  article-title: Bone morphology in response to alendronate as seen by high-resolution computed tomography: through a glass darkly
  publication-title: J Bone Miner Res
– volume: 24
  start-page: 75
  year: 2010
  end-page: 81
  ident: bb0040
  article-title: Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?
  publication-title: J Orthop Trauma
– volume: 206
  start-page: 489
  year: 1965
  end-page: 490
  ident: bb0005
  article-title: Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling
  publication-title: Nature
– volume: 305
  start-page: 783
  year: 2011
  end-page: 789
  ident: bb0045
  article-title: Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women
  publication-title: JAMA
– volume: 364
  start-page: 1728
  year: 2011
  end-page: 1737
  ident: bb0090
  article-title: Bisphosphonate use and atypical fractures of the femoral shaft
  publication-title: N Engl J Med
– volume: 363
  start-page: 2473
  year: 2010
  end-page: 2474
  ident: bb0075
  article-title: Teriparatide therapy for alendronate-associated osteonecrosis of the jaw
  publication-title: N Engl J Med
– volume: 96
  start-page: 2675
  year: 2011
  end-page: 2680
  ident: bb0070
  article-title: Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide
  publication-title: J Clin Endocrinol Metab
– volume: 49
  start-page: 1279
  year: 2011
  end-page: 1289
  ident: bb0125
  article-title: Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects
  publication-title: Bone
– volume: 3
  start-page: 52
  year: 2005
  end-page: 56
  ident: bb0020
  article-title: Bone architecture and fracture
  publication-title: Curr Osteoporos Rep
– volume: 5
  start-page: 317
  year: 2005
  ident: bb0030
  article-title: Structural heterogeneity in bone: good or bad?
  publication-title: J Musculoskelet Neuronal Interact
– volume: 96
  start-page: 1627
  year: 2011
  end-page: 1632
  ident: bb0065
  article-title: Teriparatide, vitamin d, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy
  publication-title: J Clin Endocrinol Metab
– year: 2011
  ident: bb0085
  article-title: A method and system for analysis of selected tissues
– volume: 89
  start-page: 130
  year: 2011
  end-page: 139
  ident: bb0150
  article-title: Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months
  publication-title: Calcif Tissue Int
– volume: 20
  start-page: 887
  year: 2009
  end-page: 894
  ident: bb0110
  article-title: Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate
  publication-title: Osteoporos Int
– volume: 39
  start-page: 872
  year: 2006
  end-page: 879
  ident: bb0135
  article-title: Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate
  publication-title: Bone
– volume: 21
  start-page: 366
  year: 2006
  end-page: 373
  ident: bb0160
  article-title: A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide
  publication-title: J Bone Miner Res
– volume: 29
  start-page: 1
  year: 2011
  ident: 10.1016/j.bone.2012.10.006_bb0025
  article-title: Role of trabecular microarchitecture in the formation, accumulation, and morphology of microdamage in human cancellous bone
  publication-title: J Orthop Res
  doi: 10.1002/jor.21448
– volume: 15
  start-page: 613
  year: 2000
  ident: 10.1016/j.bone.2012.10.006_bb0130
  article-title: Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib
  publication-title: J Bone Miner Res
  doi: 10.1359/jbmr.2000.15.4.613
– volume: 6
  start-page: 329
  year: 1998
  ident: 10.1016/j.bone.2012.10.006_bb0080
  article-title: In vivo high resolution 3D-QCT of the human forearm
  publication-title: Technol Health Care
  doi: 10.3233/THC-1998-65-606
– volume: 20
  start-page: 887
  year: 2009
  ident: 10.1016/j.bone.2012.10.006_bb0110
  article-title: Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate
  publication-title: Osteoporos Int
  doi: 10.1007/s00198-008-0754-4
– volume: 25
  start-page: 2267
  year: 2010
  ident: 10.1016/j.bone.2012.10.006_bb0035
  article-title: Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research
  publication-title: J Bone Miner Res
  doi: 10.1002/jbmr.253
– volume: 22
  start-page: 1502
  year: 2007
  ident: 10.1016/j.bone.2012.10.006_bb0140
  article-title: Microcrack frequency and bone remodelling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study
  publication-title: J Bone Miner Res
  doi: 10.1359/jbmr.070609
– volume: 89
  start-page: 130
  year: 2011
  ident: 10.1016/j.bone.2012.10.006_bb0150
  article-title: Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months
  publication-title: Calcif Tissue Int
  doi: 10.1007/s00223-011-9500-6
– volume: 24
  start-page: 75
  year: 2010
  ident: 10.1016/j.bone.2012.10.006_bb0040
  article-title: Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?
  publication-title: J Orthop Trauma
  doi: 10.1097/BOT.0b013e3181b6499b
– volume: 47
  start-page: 169
  year: 2010
  ident: 10.1016/j.bone.2012.10.006_bb0100
  article-title: Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies
  publication-title: Bone
  doi: 10.1016/j.bone.2010.05.019
– volume: 364
  start-page: 1728
  year: 2011
  ident: 10.1016/j.bone.2012.10.006_bb0090
  article-title: Bisphosphonate use and atypical fractures of the femoral shaft
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1010650
– volume: 87
  start-page: 1
  year: 2010
  ident: 10.1016/j.bone.2012.10.006_bb0145
  article-title: Parathyroid hormone and bone healing
  publication-title: Calcif Tissue Int
  doi: 10.1007/s00223-010-9360-5
– volume: 93
  start-page: 1583
  year: 2011
  ident: 10.1016/j.bone.2012.10.006_bb0055
  article-title: Parathyroid hormone 1–84 accelerates fracture-healing in pubic bones of elderly osteoporotic women
  publication-title: J Bone Joint Surg
  doi: 10.2106/JBJS.J.01379
– volume: 21
  start-page: 366
  year: 2006
  ident: 10.1016/j.bone.2012.10.006_bb0160
  article-title: A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide
  publication-title: J Bone Miner Res
  doi: 10.1359/JBMR.051109
– volume: 206
  start-page: 489
  year: 1965
  ident: 10.1016/j.bone.2012.10.006_bb0005
  article-title: Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling
  publication-title: Nature
  doi: 10.1038/206489a0
– volume: 39
  start-page: 872
  year: 2006
  ident: 10.1016/j.bone.2012.10.006_bb0135
  article-title: Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate
  publication-title: Bone
  doi: 10.1016/j.bone.2006.04.028
– volume: 470
  start-page: 291
  year: 2012
  ident: 10.1016/j.bone.2012.10.006_bb0165
  article-title: The effect of long-term alendronate treatment on cortical thickness of the proximal femur
  publication-title: Clin Orthop Relat Res
  doi: 10.1007/s11999-011-1985-9
– volume: 42
  start-page: 591
  year: 2008
  ident: 10.1016/j.bone.2012.10.006_bb0105
  article-title: Trabecular shear stress amplification and variability in human vertebral cancellous bone: relationship with age, gender, spine level and trabecular architecture
  publication-title: Bone
  doi: 10.1016/j.bone.2007.11.011
– volume: 305
  start-page: 783
  year: 2011
  ident: 10.1016/j.bone.2012.10.006_bb0045
  article-title: Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women
  publication-title: JAMA
  doi: 10.1001/jama.2011.190
– volume: 96
  start-page: 2675
  year: 2011
  ident: 10.1016/j.bone.2012.10.006_bb0070
  article-title: Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2011-0593
– volume: 26
  start-page: 553
  year: 2011
  ident: 10.1016/j.bone.2012.10.006_bb0095
  article-title: Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007
  publication-title: J Bone Miner Res
  doi: 10.1002/jbmr.233
– volume: 21
  start-page: 855
  year: 2006
  ident: 10.1016/j.bone.2012.10.006_bb0155
  article-title: Teriparatide increases bone formation in modeling and remodelling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis
  publication-title: J Bone Miner Res
  doi: 10.1359/jbmr.060314
– volume: 96
  start-page: 1627
  year: 2011
  ident: 10.1016/j.bone.2012.10.006_bb0065
  article-title: Teriparatide, vitamin d, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2010-2520
– volume: 5
  start-page: 317
  year: 2005
  ident: 10.1016/j.bone.2012.10.006_bb0030
  article-title: Structural heterogeneity in bone: good or bad?
  publication-title: J Musculoskelet Neuronal Interact
– volume: 164
  start-page: 2024
  year: 2004
  ident: 10.1016/j.bone.2012.10.006_bb0050
  article-title: Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.164.18.2024
– volume: 25
  start-page: 404
  year: 2010
  ident: 10.1016/j.bone.2012.10.006_bb0060
  article-title: Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures
  publication-title: J Bone Miner Res
  doi: 10.1359/jbmr.090731
– volume: 354
  start-page: 2250
  year: 2006
  ident: 10.1016/j.bone.2012.10.006_bb0010
  article-title: Bone quality–the material and structural basis of bone strength and fragility
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra053077
– volume: 363
  start-page: 2473
  year: 2010
  ident: 10.1016/j.bone.2012.10.006_bb0075
  article-title: Teriparatide therapy for alendronate-associated osteonecrosis of the jaw
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc1002684
– volume: 49
  start-page: 1279
  year: 2011
  ident: 10.1016/j.bone.2012.10.006_bb0125
  article-title: Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects
  publication-title: Bone
  doi: 10.1016/j.bone.2011.09.042
– volume: 25
  start-page: 2553
  year: 2010
  ident: 10.1016/j.bone.2012.10.006_bb0015
  article-title: Bone morphology in response to alendronate as seen by high-resolution computed tomography: through a glass darkly
  publication-title: J Bone Miner Res
  doi: 10.1002/jbmr.261
– volume: 35
  start-page: 1240
  year: 2004
  ident: 10.1016/j.bone.2012.10.006_bb0120
  article-title: Effect of aging on the toughness of human cortical bone: evaluation by R-curves
  publication-title: Bone
  doi: 10.1016/j.bone.2004.07.016
– volume: 88
  start-page: 1150
  year: 2003
  ident: 10.1016/j.bone.2012.10.006_bb0170
  article-title: Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2002-021988
– year: 2011
  ident: 10.1016/j.bone.2012.10.006_bb0085
– volume: 3
  start-page: 52
  year: 2005
  ident: 10.1016/j.bone.2012.10.006_bb0020
  article-title: Bone architecture and fracture
  publication-title: Curr Osteoporos Rep
  doi: 10.1007/s11914-005-0004-z
– volume: 2
  start-page: 1
  year: 1969
  ident: 10.1016/j.bone.2012.10.006_bb0115
  article-title: The mechanical consequences of variation in the mineral content of bone
  publication-title: J Biomech
  doi: 10.1016/0021-9290(69)90036-0
SSID ssj0003971
Score 2.4422855
Snippet Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone, when...
Abstract Bone remodelling suppressants like the bisphosphonates reduce bone loss and slow progression of structural decay. As remodelling removes damaged bone,...
SourceID proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 360
SubjectTerms Aged
Atypical femur fractures
Biological and medical sciences
Bisphosphonates
Bone (cortical)
Bone density
Bone Density Conservation Agents - pharmacology
Bone Density Conservation Agents - therapeutic use
Bone healing
Bone loss
Bone remodelling
Bones, joints and connective tissue. Antiinflammatory agents
Computed tomography
Computer programs
Diphosphonates - adverse effects
Female
Femoral Fractures - chemically induced
Femur
Fracture Healing - drug effects
Fractures
Fundamental and applied biological sciences. Psychology
High resolution computed tomography
Humans
Injuries of the limb. Injuries of the spine
Male
Medical sciences
Mineralization
Orthopedics
Osteoporosis
Pain
Parathyroid hormone
Pharmacology. Drug treatments
Prospective Studies
Radius
Sex
software
Teriparatide
Teriparatide - pharmacology
Teriparatide - therapeutic use
Tibia
Traumas. Diseases due to physical agents
Vertebrates: anatomy and physiology, studies on body, several organs or systems
Title Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy
URI https://www.clinicalkey.com/#!/content/1-s2.0-S8756328212013130
https://www.clinicalkey.es/playcontent/1-s2.0-S8756328212013130
https://dx.doi.org/10.1016/j.bone.2012.10.006
https://www.ncbi.nlm.nih.gov/pubmed/23072919
https://www.proquest.com/docview/1221848650
https://www.proquest.com/docview/1257751265
Volume 52
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1di9QwcDj3QAQRvfNj_VgiiC_S203SNu3jcnisyt2Ld3BvIWlSXNFusbsP--Jvd6ZJVw69FXwohdBpppnJfHVmAvBGWlmiYjUJd84kaW5MYnhdJxU1c0tVXVtHtcPnF_niKv14nV0fwOlQC0NplVH2B5neS-s4Mo2rOW2Xy-lntLRziR4DF9QzRqLffihQ2xcjOJx_-LS42AlkVLk8hPnyhABi7UxI87KrhrplcnESkrxu00_3W9PhqtXhuIvb7dFeL509hAfRoGTzgPMjOPDNERzPG3Smv2_ZW9anePax8yO4ex7_pB9Dd4msF_p-O8-WfWjBd4zwZKHQcstM4xgZkqjd2KpmZr1tiaSspuxculOF1Qb9dWYikb1jFNhldtm1X1Z0IR6ehSKv7WO4Ont_ebpI4gEMSZXl5Tpxaekk7uiCV7NKmcwY66TwaVEWlsrPhUUDRwnvfeoktZXxBTc8deXMGGkzK5_AqEG8nwFz3nF8R-GKskod-lwmy31hUuXLrFZGjYEPy66r2J2cDsn4poc0tK-alkATqWgMSTWGdzuYNvTm2Pu0HKiph6pTlJMaVcdeKPU3KN_Frd5prjuhZ_oPdhxDtoO8wdH_nHFyg9V2nyYUaqdZysfweuA9jbKAfvCYxq82iIogh71Ao3vfM5lSaOXl2RieBsb9PYOkPvK8fP6fqL-Ae6I_LYQiVC9htP6x8a_QZlvbCdw5-ckncWf-AqzLQYM
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1da9sw8CgpbIMxtnYf3kenwdjL8BJZsmU_hrKSrk1elkLfhGzJNGNzwpw85N_vzpIzytYM9mAMxmefdaf78n0AvBelKFCxmphba2KZGRMbXtdxRc3cpKrr0lLt8HSWTa7kl-v0-gBO-1oYSqsMst_L9E5ahyvDsJrD1WIx_IqWdibQY-AJ9YwR6LcfShpqPYDD8fnFZLYTyKhyuQ_zZTEBhNoZn-ZVLhvqlsmTTz7J6y799HBlWly12o-7uNse7fTS2WN4FAxKNvY4P4ED1xzB8bhBZ_rHln1gXYpnFzs_gnvT8Cf9GNo5sp7v-20dW3ShBdcywpP5QsstM41lZEiidmPLmpn1dkUkZTVl59KZKqw26K8zE4jsLKPALisX7epmSQfi4Zgv8to-hauzz_PTSRwGMMRVmhXr2MrCCtzROa9GlTKpMaUViZN5kZdUfp6UaOCoxDknraC2Mi7nhktbjIwRZVqKZzBoEO8XwKyzHJ-R27yopEWfy6SZy41UrkhrZVQEvF92XYXu5DQk47vu09C-aVoCTaSia0iqCD7uYFa-N8feu0VPTd1XnaKc1Kg69kKpv0G5Nmz1VnPdJnqk_2DHCNId5C2O_ucbT26x2u7TEoXaaSR5BO963tMoC-gHj2nccoOoJOSw52h077snVQqtvCyN4Lln3N9vENRHnhcv_xP1t3B_Mp9e6svz2cUreJB0k0MoWvUaBuufG_cG7bd1eRL25y85O0Np
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Teriparatide+improves+bone+quality+and+healing+of+atypical+femoral+fractures+associated+with+bisphosphonate+therapy&rft.jtitle=Bone+%28New+York%2C+N.Y.%29&rft.au=Chiang%2C+Cherie+Ying&rft.au=Zebaze%2C+Roger+M.D.&rft.au=Ghasem-Zadeh%2C+Ali&rft.au=Iuliano-Burns%2C+Sandra&rft.date=2013-01-01&rft.pub=Elsevier+Inc&rft.issn=8756-3282&rft.eissn=1873-2763&rft.volume=52&rft.issue=1&rft.spage=360&rft.epage=365&rft_id=info:doi/10.1016%2Fj.bone.2012.10.006&rft.externalDocID=S8756328212013130
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F87563282%2FS8756328212X00140%2Fcov150h.gif